Valneva SE (VALN) 주식 분석

회사 개요

Valneva SE is a specialty vaccine company dedicated to the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases that address significant unmet medical needs. Within the healthcare sector, specifically the biotechnology industry, the company focuses on creating immunization solutions, most notably offering IXIARO, an inactivated Vero cell culture-derived vaccine indicated for active immunization against Japanese encephalitis. The organization operates with a workforce of 674 employees and holds a market capitalization of $561.35M, generating an annual revenue of $174.66M over the trailing twelve months. These financial metrics indicate that Valneva functions as a mid-sized enterprise within the specialized vaccine market, where revenue figures reflect the scale of commercialization efforts for its core infectious disease products while the market cap suggests a valuation sensitive to clinical development milestones and regulatory approvals.

재무 건전성

The company reported a revenue of $174.66M for the trailing twelve months, yet this generated a net income of $-115,192,000, highlighting a substantial gap between top-line sales and bottom-line profitability that points to a heavy cost structure or significant operating losses. This negative net income is further supported by an EBITDA figure of $-64,702,000, indicating that even before interest, taxes, depreciation, and amortization, the core operations are not yet cash-generative. The company's free cash flow stands at $-49,673,376, which implies limited financial flexibility as the business currently requires external capital to fund operations and potentially research and development activities. Margin analysis reveals a gross margin of -10.2%, an operating margin of -58.1%, and a profit margin of -66.0%, all of which indicate that current costs exceed gross sales and that the company is absorbing significant expenses relative to its revenue base. In terms of leverage, Valneva holds $109.65M in cash against $207.25M in debt, resulting in a debt-to-equity ratio of 195.21, which characterizes the balance sheet as highly leveraged rather than conservative. Despite this leverage, the current ratio of 2.38 suggests that the company maintains adequate short-term liquidity to cover its immediate obligations. Finally, the return on equity is recorded at -80.2% and the return on assets at -11.4%, metrics that reveal that management has not yet generated positive returns on shareholder capital or the asset base due to the prevailing loss-making environment.

밸류에이션 평가

Valneva SE does not have a trailing P/E ratio as earnings are negative, but it trades at a forward P/E of 7.72, a divergence that implies the market is pricing in a future trajectory of earnings turnaround or recovery rather than current profitability. The price-to-book ratio is 8.82, indicating that the market values the company at a significant premium over its tangible book value, likely reflecting the intangible nature of its vaccine pipeline and intellectual property. Alternative valuation metrics such as the price-to-sales ratio of 3.21 and the EV/EBITDA of -18.26 provide additional context, suggesting the market is willing to pay a high multiple for revenue despite the negative earnings multiple. Regarding price volatility, the stock has a 52-week high of $12.25 and a 52-week low of $5.43, meaning the current price sits in a range that fluctuates significantly based on clinical trial results and partnership announcements. The beta value of 1.53 indicates that the stock's price volatility is substantially higher than the broader market, making it a higher-risk investment component compared to large-cap stable stocks.

Growth & Income

The company experienced a revenue growth rate of -9.9% year-over-year, while earnings growth is marked as N/A due to negative earnings, implying that the decline in revenue is directly impacting profitability without the potential for earnings to grow faster than sales in the current period. As a non-dividend payer, Valneva does not distribute a dividend yield or a payout ratio, meaning the company reinvests all available earnings back into growth initiatives such as R&D and manufacturing capacity rather than returning cash to shareholders. This reinvestment strategy is typical for biotechnology firms in the development phase, where capital is prioritized for product advancement over shareholder distributions. Overall, the growth and income profile is characterized by revenue contraction in the recent period and a complete absence of dividend income, positioning the asset purely for capital appreciation potential dependent on future operational improvements.